Thank you for sharing!

Your article was successfully shared with the contacts you provided.
As state laws collide with federal regs, drug companies must learn to adapt.
• When the FDA Acts, State Torts Must Defer FDA approval of drug labels ought to pre-empt state claims, as courts have recently noted. by Daniel E. Troy • Promoting Off-Label Use is Good for Us Despite federal warnings, promotion of off-label drug uses actually improves public health. by Rene Quashie • A National, Uniform Paper Trail for Drugs? States are starting to require drug “pedigrees,” but a national standard may be on the way. by Peter S. Reichertz and Deborah M. Shelton • Please Watch Me to See If I Ever Get Sick Medical-monitoring claims are being brought against drug makers, and that’s not a good idea. by Sean P. Wajert

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 1 article* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.